Enrollees in silver plans through the exchanges could be paying more than twice as much on prescription drugs than they would under a typical employer plan, new research finds.

The report — commissioned by the Pharmaceutical Research and Manufacturers of America and conducted by actuarial firm Milliman — found exchange participants are paying a "far larger increase in out-of-pocket costs than was found for other medical care."

Overall, the report found that silver plan enrollees would likely pay 130 percent more for out-of-pocket prescription drugs compared to people on similar employer-sponsored plans.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.